期刊
JOURNAL OF CLINICAL NEUROSCIENCE
卷 22, 期 12, 页码 1889-1894出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.jocn.2015.06.005
关键词
Doxorubicin; Epidermal growth factor receptor; First in human; Glioblastoma; Phase I trial
资金
- EnGeneIC (Lane Cove West, NSW, Australia)
There are limited treatment options for patients with recurrent glioblastoma (GBM). The EnGeneIC delivery vehicle (EDV) is a novel nanocellular (minicell) compound which packages theoretically effective concentrations of chemotherapeutic drugs that are designed to target tumors via minicell-surface attached bispecific proteins (EnGeneIC, Lane Cove West, NSW, Australia). Epidermal growth factor receptor (EGFR) is overexpressed in 40-50% of patients with GBM and is a promising target for new therapeutics. (EDVDox)-E-V contains doxorubicin (Dox) within the minicells and targets EGFR through Vectibix (V; Amgen Biologicals, Thousand Oaks, CA, USA). We conducted a first in human Phase I study of (EDVDox)-E-V in adults with recurrent GBM expressing EGFR on immunohistochemistry, following standard therapy including radiation and temozolomide, to establish a safe maximum tolerated dose and determine a recommended Phase II dose (RPTD). (EDVDox)-E-V was administered weekly in an 8 week cycle, with dose escalation in successive cohorts of patients using a standard 3 + 3 design. In total, 14 patients were treated at three dose levels, and the RPTD was identified as 5 x 109 (EDVDox)-E-V. Overall (EDVDox)-E-V was well tolerated, with no dose limiting toxicity and no withdrawals from the study due to adverse events. The most common adverse events were nausea, fever, and chills or rigors, experienced in seven, five and five patients, respectively. Transient uncomplicated hypophosphatemia was seen in seven patients and was not dose-related. Our results demonstrate that (EDVDox)-E-V, up to a dose of 5 x 10(9) (EDVDox)-E-V. weekly, is well tolerated in patients with recurrent GBM. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据